US 10590090
2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors
granted A61PA61P35/02A61P35/04
Quick answer
US patent 10590090 (2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors) held by Revolution Medicines, Inc. expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Revolution Medicines, Inc.
- Grant date
- Tue Mar 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 50
- CPC classes
- A61P, A61P35/02, A61P35/04